Pharma Focus: Zometa (zoledronic acid)

Article

Breast and other solid tumors often metastasize to the bones, creating osteolytic or osteoblastic lesions, which make bones fragile and prone to breaking.

Breast and other solid tumors often metastasize to the bones, creating osteolytic or osteoblastic lesions, which make bones fragile and prone to breaking. Zometa is a third-generation biphosphonate developed by Novartis that has been found to help delay, prevent, or reduce skeletal damage caused by metastases to the bones. Zometa reduces the risk of bone complications such as fractures, hypercalcemia of malignancy, spinal cord compression, and more. Even patients who have already suffered complications may benefit from taking Zometa. Full prescribing information for Zometa can be accessed at http://tinyurl.com/ylnww25.

Related Videos
3 KOLs are featured in this program.
3 KOLs are featured in this program.
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Edward V Loftus, Jr, MD | Credit: Mayo Clinic
A panel of 4 experts on asthma
A panel of 4 experts on asthma
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
© 2024 MJH Life Sciences

All rights reserved.